Stock listing
NASDAQ:GNLX Genelux Corporation Stock
Home listing (NASDAQ) of Genelux Corporation
Follow Genelux Corporation into a list and get an email when it puts out news.
Share price · NASDAQ:GNLX
$2.17 USD -0.07 (-3.1%)
Close on Nov 20, 2026
- Day range
- $2.12 – $2.41 USDNov 20, 2026
- Volume
- 316,371 sharesNov 20, 2026
- Market cap
- $104.3M USDAt the close on Nov 20, 2026 · price × 48.06M shares outstanding
- 52-week range
- $1.77 – $5.89 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $777,957 USDMedian day 278,256 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GNLX · Home | $2.17 USD | -0.07 (-3.1%) | 316,371 | $2.27 | $2.41 | $2.12 | $2.24 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GNLX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.17 | -0.07 | -3.1% | $2.27 | $2.41 | $2.12 | 316,371 | |
| $2.24 | +0.24 | +12.0% | $2.00 | $2.29 | $2.00 | 801,127 | |
| $2.00 | +0.08 | +4.2% | $1.84 | $2.05 | $1.82 | 251,278 | |
| $1.92 | +0.055 | +2.9% | $1.94 | $2.02 | $1.855 | 277,009 | |
| $1.865 | -0.035 | -1.8% | $1.92 | $1.96 | $1.83 | 179,403 | |
| $1.90 | +0.02 | +1.1% | $1.88 | $1.95 | $1.81 | 137,319 | |
| $1.88 | -0.07 | -3.6% | $1.97 | $2.00 | $1.86 | 292,410 | |
| $1.95 | -0.12 | -5.8% | $2.01 | $2.10 | $1.92 | 93,183 | |
| $2.07 | +0.11 | +5.6% | $2.03 | $2.09 | $1.935 | 234,713 | |
| $1.96 | +0.14 | +7.7% | $1.83 | $2.02 | $1.81 | 323,773 | |
| $1.82 | -0.14 | -7.1% | $1.94 | $1.94 | $1.77 | 228,582 | |
| $1.96 | +0.04 | +2.1% | $1.95 | $2.01 | $1.862 | 310,505 | |
| $1.92 | -0.08 | -4.0% | $2.01 | $2.065 | $1.91 | 287,998 | |
| $2.00 | -0.08 | -3.8% | $2.11 | $2.18 | $1.952 | 523,901 | |
| $2.08 | -0.02 | -1.0% | $2.07 | $2.11 | $2.00 | 209,629 | |
| $2.10 | -0.11 | -5.0% | $2.27 | $2.27 | $2.085 | 120,301 | |
| $2.21 | +0.16 | +7.8% | $2.06 | $2.24 | $1.98 | 523,908 | |
| $2.05 | +0.14 | +7.3% | $1.92 | $2.07 | $1.86 | 1,451,693 | |
| $1.91 | -0.09 | -4.5% | $2.00 | $2.12 | $1.87 | 494,700 | |
| $2.00 | +0.02 | +1.0% | $2.02 | $2.07 | $1.90 | 648,745 | |
| $1.98 | -0.09 | -4.3% | $2.04 | $2.35 | $1.96 | 947,444 | |
| $2.07 | -0.43 | -17.2% | $2.53 | $2.57 | $2.018 | 850,725 | |
| $2.50 | +0.05 | +2.0% | $2.43 | $2.612 | $2.43 | 331,726 | |
| $2.45 | +0.03 | +1.2% | $2.42 | $2.47 | $2.40 | 161,491 | |
| $2.42 | -0.06 | -2.4% | $2.48 | $2.52 | $2.355 | 277,873 | |
| $2.48 | +0.16 | +6.9% | $2.40 | $2.51 | $2.33 | 796,526 | |
| $2.32 | -0.20 | -7.9% | $2.48 | $2.52 | $2.32 | 410,559 | |
| $2.52 | -0.025 | -1.0% | $2.53 | $2.54 | $2.485 | 151,876 | |
| $2.545 | -0.015 | -0.6% | $2.59 | $2.59 | $2.51 | 72,617 | |
| $2.56 | +0.06 | +2.4% | $2.48 | $2.57 | $2.47 | 154,650 | |
| $2.50 | -0.02 | -0.8% | $2.47 | $2.53 | $2.42 | 259,115 | |
| $2.52 | -0.02 | -0.8% | $2.52 | $2.59 | $2.46 | 550,979 | |
| $2.54 | -0.06 | -2.3% | $2.58 | $2.63 | $2.52 | 77,647 | |
| $2.60 | +0.04 | +1.6% | $2.55 | $2.66 | $2.465 | 317,345 | |
| $2.56 | +0.04 | +1.6% | $2.55 | $2.59 | $2.515 | 278,256 | |
| $2.52 | -0.01 | -0.4% | $2.53 | $2.56 | $2.46 | 200,900 | |
| $2.53 | +0.08 | +3.3% | $2.47 | $2.55 | $2.47 | 236,870 | |
| $2.45 | -0.02 | -0.8% | $2.48 | $2.56 | $2.415 | 164,897 | |
| $2.47 | -0.01 | -0.4% | $2.46 | $2.50 | $2.41 | 103,751 | |
| $2.48 | +0.05 | +2.1% | $2.47 | $2.54 | $2.42 | 139,873 | |
| $2.43 | -0.085 | -3.4% | $2.51 | $2.524 | $2.41 | 151,993 | |
| $2.515 | -0.095 | -3.6% | $2.61 | $2.64 | $2.50 | 115,792 | |
| $2.61 | +0.05 | +2.0% | $2.55 | $2.63 | $2.52 | 161,803 | |
| $2.56 | +0.03 | +1.2% | $2.57 | $2.585 | $2.51 | 197,287 | |
| $2.53 | 0.00 | 0.0% | $2.54 | $2.565 | $2.504 | 143,118 | |
| $2.53 | +0.19 | +8.1% | $2.36 | $2.56 | $2.36 | 295,280 | |
| $2.34 | -0.13 | -5.3% | $2.47 | $2.47 | $2.31 | 661,722 | |
| $2.47 | -0.07 | -2.8% | $2.61 | $2.61 | $2.40 | 203,404 | |
| $2.54 | +0.05 | +2.0% | $2.49 | $2.61 | $2.46 | 297,586 | |
| $2.49 | +0.01 | +0.4% | $2.53 | $2.55 | $2.448 | 146,907 | |
| $2.48 | -0.04 | -1.6% | $2.55 | $2.73 | $2.41 | 535,584 | |
| $2.52 | -0.02 | -0.8% | $2.50 | $2.555 | $2.485 | 114,099 | |
| $2.54 | +0.10 | +4.1% | $2.50 | $2.54 | $2.39 | 408,292 | |
| $2.44 | -0.08 | -3.2% | $2.52 | $2.535 | $2.425 | 296,534 | |
| $2.52 | -0.03 | -1.2% | $2.55 | $2.58 | $2.46 | 510,440 | |
| $2.55 | -0.05 | -1.9% | $2.58 | $2.635 | $2.55 | 158,137 | |
| $2.60 | -0.015 | -0.6% | $2.63 | $2.66 | $2.56 | 194,989 | |
| $2.615 | -0.045 | -1.7% | $2.67 | $2.77 | $2.56 | 328,487 | |
| $2.66 | -0.22 | -7.6% | $2.87 | $2.87 | $2.65 | 417,797 | |
| $2.88 | +0.15 | +5.5% | $2.72 | $2.95 | $2.72 | 594,425 | |
| $2.73 | +0.01 | +0.4% | $2.73 | $2.756 | $2.64 | 300,182 | |
| $2.72 | 0.00 | 0.0% | $2.73 | $2.82 | $2.67 | 352,906 | |
| $2.72 | 0.00 | 0.0% | $2.70 | $2.77 | $2.57 | 361,056 | |
| $2.72 | -0.02 | -0.7% | $2.78 | $2.81 | $2.684 | 223,747 | |
| $2.74 | +0.06 | +2.2% | $2.72 | $2.80 | $2.62 | 405,118 |
- Ticker
- NASDAQ:GNLX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 16, 2026
Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 46 slides
Latest news
Genelux Corporation Reports Third Quarter Financial Results and Provides Business Updates
Nov 16, 2026
Closed $2.00 (+4.2%) on Nov 17, 2026
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
Sep 9, 2026
Closed $2.48 (-1.6%) on Sep 10, 2026
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
Aug 13, 2026
Closed $2.74 (+4.2%) on Aug 14, 2026
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
Jun 30, 2026
Closed $3.01 (+3.8%) on Jun 30, 2026
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026
Closed $3.11 (+9.9%) on May 8, 2026
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Mar 19, 2026
Closed $2.40 (-5.5%) on Mar 20, 2026
Genelux Corporation to Participate in Upcoming Conferences
Feb 18, 2026
Closed $2.62 (+2.3%) on Feb 18, 2026
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
Jan 12, 2026
Closed $2.74 (+3.4%) on Jan 13, 2026
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
Jan 8, 2026
Closed $2.72 (-19.8%) on Jan 8, 2026
Genelux Corporation Announces Proposed Public Offering of Common Stock
Jan 7, 2026
Closed $2.72 (-19.8%) on Jan 8, 2026
Genelux Corporation on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 42 in all · newest Nov 16, 2026 · oldest 2023
- Decks
- 17 decks · latest August 2026
Where Genelux Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GNLX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:GNLX | BOATS | United States | USD |
Valuation
EV/sales 11,732× against a median of 22.3×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $93.85M USD
- P/E
- Loss
- EV/sales
- 11,732×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 11.4×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.52
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Paradigm Biopharmaceuticals Ltd. · ASX:PAR | US$101.6M | US$96.33M | n/a | 1,816× | n/a | 44.2× | n/a | 2.2× | n/a |
| Innate Pharma SA Class A · EURONEXT:IPH | US$101.5M | US$111.7M | n/a | 36.5× | n/a | n/a | n/a | n/a | n/a |
| BRIM Biotechnology, Inc. · TWSE:6885 | US$100.3M | US$70.71M | n/a | 220× | n/a | 2.1× | n/a | 0.0× | n/a |
| Median of the others | US$103.2M | US$83.89M | 10.9× | 22.3× | −2.5× | 3.8× | −195.8% | 0.0× | 1.51 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.83 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.86 · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas Zindrick | President and Chief Executive Officer |
| Matt Pulisic | Chief Financial Officer |
| Eric Groen | General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development |
| Qian Zhang | Vice President, Clinical Sciences |
| Ralph Smalling | Vice President, Head of Regulatory Affairs |
| Jason Litten | Chief Medical Officer |
| Joseph Cappello | Chief Technical Officer |
| Tony Yu | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Thomas Zindrick | President and Chief Executive Officer |
| James L. Tyree | Lead Independent Director |
| John Smither | Chair, Compensation Committee |
| John Thomas | Chair, Audit Committee |
| Mary Mirabelli | Chair, Nominating and Corporate Governance Committee |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 16, 2026 · After close | +4.2% |
| Q2 2026 | Aug 13, 2026 · After close | +4.2% |
| Q1 2026 | May 7, 2026 · After close | +9.9% |
| Q4 2025 | Mar 20, 2026 | −2.4% |
| Q3 2025 | Nov 5, 2025 | −34.6% |
| Q2 2025 | Aug 7, 2025 | −12.3% |
| Q1 2025 | May 6, 2025 · After close | −0.4% |
| Q4 2024 | Mar 28, 2025 | −10.9% |
| Q3 2024 | Nov 14, 2024 · After close | −19.7% |
| Q2 2024 | Aug 14, 2024 · After close | +1.9% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −4.7% |
| Q4 2023 | Mar 29, 2024 · After close | −18.5% |
| Q3 2023 | Nov 14, 2023 · After close | −7.6% |
| Q2 2023 | Aug 14, 2023 · Before open | −1.3% |
| Q1 2023 | May 15, 2023 · Before open | −9.1% |
| Q4 2022 | Mar 29, 2023 · After close | +2.6% |
| Q2 2022 | Sep 19, 2022 | |
| Q1 2022 | Jun 24, 2022 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 46 slides | August 2026 |
| Investor Presentation (February 2026) | Investor deck | 45 slides | Feb 2, 2026 |
| Investor Presentation (March 2025) | Investor deck | 43 slides | Mar 25, 2025 |
| Investor Presentation (November 2024) | Investor deck | 41 slides | Nov 8, 2024 |
| Investor Presentation (August 2024) | Investor deck | 28 slides | Aug 1, 2024 |
| Investor Presentation (June 2024) | Investor deck | 40 slides | Jun 5, 2024 |
| Investor Presentation (May 2024) | Investor deck | 40 slides | May 24, 2024 |
| Investor Presentation (April 2024) | Investor deck | 40 slides | Apr 9, 2024 |
| Investor Presentation (April 2024) | Investor deck | 39 slides | Apr 2, 2024 |
| Investor Presentation (February 2024) | Investor deck | 37 slides | Feb 5, 2024 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (December 2023) | Investor deck | 37 slides | Dec 12, 2023 |
| Investor Presentation (October 2023) | Investor deck | 38 slides | Oct 10, 2023 |
| Investor Presentation (July 2023) | Investor deck | 38 slides | Jul 19, 2023 |
| Investor Presentation (June 2023) | Investor deck | 33 slides | Jun 27, 2023 |
| IPO Roadshow (January 2023) | IPO roadshow | 36 slides | Jan 13, 2023 |
| IPO Roadshow (November 2022) | IPO roadshow | 36 slides | Nov 4, 2022 |
| Investor Presentation (August 2021) | Investor deck | 25 slides | Aug 1, 2021 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of common stock Tranche closed: US$5.1M raised Use of proceeds: Together with existing cash, expected to fund operations into the first quarter of 2027 | Nov 16, 2026 |
| Public offering of common stock Announced: about US$20M · US$3 a share · Lucid Capital Markets Dealers: Lucid Capital Markets (lead) Use of proceeds: General corporate purposes, possibly including research and development, clinical trial expenses, capital expenditures and working capital | Jan 8, 2026 |
| Public offering of common stock Closed: US$10.5M raised · US$3.5 a share · Titan Partners Group, a division of American Capital Partners Dealers: Titan Partners Group, a division of American Capital Partners (lead) Use of proceeds: Working capital and general corporate purposes, including continued clinical development of Olvi-Vec | Mar 28, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$6.00 a share on Jan 25, 2023.
- Price
- US$6.00 a share
- Shares offered
- 2,500,000 shares of common stock
- Offering size
- US$15 million
- Underwriters' option
- Up to 375,000 more shares
- Underwriters
- The Benchmark Company, Brookline Capital Markets · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 7, 2021 |
| Filed publicly | Jun 24, 2022 |
| Amended 6 times | Newest Jan 10, 2023 |
| Shares registered with an exchange | Jan 23, 2023 |
| Declared effective by the SEC | Jan 25, 2023 |
| Final prospectus, with the price | Jan 26, 2023 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jan 26, 2023 |
| CERT · Exchange's certificate of listing | Jan 26, 2023 |
| EFFECT · Notice that a registration is effective | Jan 25, 2023 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 23, 2023 |
| CORRESP · Letter to the SEC | Jan 23, 2023 |
| CORRESP · Letter to the SEC | Jan 23, 2023 |
| FWP · Free writing prospectus | Jan 13, 2023 |
| S-1/A · Registration statement, amended | Jan 10, 2023 |
| S-1/A · Registration statement, amended | Dec 23, 2022 |
| FWP · Free writing prospectus | Nov 4, 2022 |
All 31 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 4, 2022 |
| S-1/A · Registration statement, amended | Nov 4, 2022 |
| UPLOAD · Letter from the SEC | Nov 3, 2022 |
| CORRESP · Letter to the SEC | Oct 13, 2022 |
| S-1/A · Registration statement, amended | Oct 13, 2022 |
| FWP · Free writing prospectus | Oct 4, 2022 |
| UPLOAD · Letter from the SEC | Sep 29, 2022 |
| S-1/A · Registration statement, amended | Sep 19, 2022 |
| CORRESP · Letter to the SEC | Aug 29, 2022 |
| S-1/A · Registration statement, amended | Aug 29, 2022 |
| CORRESP · Letter to the SEC | Jul 8, 2022 |
| CORRESP · Letter to the SEC | Jun 24, 2022 |
| S-1 · Registration statement | Jun 24, 2022 |
| UPLOAD · Letter from the SEC | Jun 14, 2022 |
| DRSLTR · Letter to the SEC with a draft | May 20, 2022 |
| DRS/A · Draft registration statement, amended | May 20, 2022 |
| UPLOAD · Letter from the SEC | Jul 7, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 24, 2021 |
| DRS/A · Draft registration statement, amended | Jun 24, 2021 |
| UPLOAD · Letter from the SEC | Jun 3, 2021 |
| DRS · Draft registration statement | May 7, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2023
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.00K | 8.00K | 170.0K | 11.1M | 0 | 0 | |
| Cost of revenue | 574.0K | 903.0K | 1.02M | 968.0K | 895.0K | 658.0K | 477.0K |
| Gross profit | -566.0K | -895.0K | -848.0K | 10.1M | -895.0K | -658.0K | -477.0K |
| Research and development | 19.9M | 19.0M | 12.8M | 9.08M | 6.32M | 6.23M | 7.53M |
| Selling, general and administrative | 13.4M | 12.7M | 11.6M | 5.00M | 8.29M | 6.20M | 3.13M |
| Operating income | -33.2M | -31.7M | -24.2M | -3.01M | -14.6M | -12.4M | -10.9M |
| Depreciation and amortization | 244.0K | 235.0K | 499.0K | 553.0K | 895.0K | 658.0K | 477.0K |
| EBITDA | -33.0M | -31.5M | -23.7M | -2.46M | -13.7M | -11.8M | -10.4M |
| Interest expense | 0 | 173.0K | 1.41M | 1.81M | 1.22M | 761.0K | |
| Income before tax | -32.1M | -29.9M | -28.3M | -4.11M | -16.4M | -13.6M | -11.6M |
| Income tax | 850.1K | 1.10M | 1.42M | 1.22M | |||
| Net income | -32.1M | -29.9M | -28.3M | -5.21M | -17.8M | -14.9M | -11.6M |
| Earnings per share, basic | -0.86 | -0.95 | -1.16 | -0.57 | -0.75 | -0.63 | -0.49 |
| Earnings per share, diluted | -0.86 | -0.95 | -1.16 | -0.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.33M | 8.56M | 9.42M | 397.0K | 4.50M | 11.3M | 425.0K |
| Short-term investments | 9.26M | 22.3M | 13.8M | 0 | |||
| Current assets | 15.1M | 31.5M | 24.2M | 1.89M | 5.82M | 11.5M | 551.0K |
| Property, plant and equipment | 2.17M | 1.32M | 1.17M | 644.0K | 2.21M | 2.45M | 2.65M |
| Total assets | 19.0M | 34.7M | 27.9M | 5.53M | 8.13M | 14.0M | 3.28M |
| Accounts payable | 4.36M | 5.57M | 3.78M | 6.78M | 4.46M | 927.0K | 3.63M |
| Current liabilities | 6.22M | 6.90M | 6.55M | 31.6M | 22.5M | 14.5M | 14.7M |
| Long-term debt | 8.52M | 18.0M | 21.7M | ||||
| Total debt | 1.69M | 1.87M | 2.52M | 26.4M | 25.3M | 26.1M | 18.0M |
| Total liabilities | 7.48M | 8.44M | 8.42M | 41.3M | 41.2M | 36.7M | 28.1M |
| Shareholders' equity | 11.5M | 26.3M | 19.5M | -35.8M | -33.1M | -22.7M | -24.8M |
| Shares outstanding | 38.1M | 34.7M | 26.8M | 9.13M | 23.6M | 23.6M | 23.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -25.3M | -21.2M | -20.3M | -3.57M | -6.58M | -7.21M | -7.22M |
| Capital spending | -1.10M | -381.0K | -1.02M | -49.0K | -49.0K | -20.0K | -1.77M |
| Free cash flow | -26.4M | -21.6M | -21.3M | -3.62M | -6.63M | -7.22M | -8.99M |
| Cash from investing | 12.1M | -8.13M | -14.7M | -49.0K | -49.0K | -20.0K | -1.77M |
| Cash from financing | 9.89M | 28.5M | 44.0M | -478.0K | -270.0K | 18.1M | 7.89M |
| Change in cash | -3.23M | -853.0K | 9.02M | -4.10M | -6.86M | 10.9M | -1.11M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 16, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 1, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2026 | Material contract | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 2, 2026 | Current report | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 7, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Jan 7, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 5, 2026 | Current report | SEC |
| 8-K · Current report | Jan 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 1, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 7, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 25, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Jul 11, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jul 11, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 11, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2025 | Annual report | SEC |
| 424B5 · Prospectus | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| FWP · Free writing prospectus | Mar 25, 2025 | Offer document | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Feb 3, 2025 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Dec 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 31, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 30, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 25, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 3, 2024 | Management or board change | SEC |
| 4/A · Change in ownership, amended | Sep 26, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 6, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 22, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 1, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Jun 14, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 14, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 14, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 4, 2024 | Current report | SEC |
| 424B5 · Prospectus | May 24, 2024 | Offer document | SEC |
| 8-K · Current report | May 24, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 23, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 24, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 18, 2024 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 11, 2024 | Other filings | SEC |
| 8-K · Current report | Apr 9, 2024 | Current report | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 29, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 29, 2024 | Annual report | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 8, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 5, 2024 | Current report | SEC |
| 8-K · Current report | Feb 2, 2024 | Results | SEC |
| S-3 · Registration statement | Feb 2, 2024 | Offer document | SEC |
| SC 13G · Big-stake notice | Feb 2, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 13, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 13, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 12, 2023 | Current report | SEC |
| 4 · Change in ownership | Dec 8, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 7, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 24, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 14, 2023 | Offer document | SEC |
This page holds 200 of 363 filings. Open Filings
Cap table
Built by 6ix from Genelux Corporation’s releases · as of Nov 16, 2026
- Common shares
- 48,064,184
- Fully diluted
- 48,064,184
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 48,064,184 | Nov 11, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 11, 2026 | 48,064,184 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John Smither Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); MBX Biosciences, Inc. (Chief Financial Officer · Since at least Mar 16, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Applied Molecular Transport Inc (Director · Jan 27, 2022 – Dec 27, 2023 · Past); eFFECTOR Therapeutics Inc (Director · Aug 25, 2020 – Jun 22, 2023 · Past); Arcutis Biotherapeutics, Inc. (Chief Financial Officer · Jan 30, 2020 – Feb 13, 2024 · Past); Principia Biopharma Inc (Director · Feb 19, 2019 – Feb 19, 2019 · Past); Achaogen Inc (Director · Mar 11, 2014 – Jun 5, 2018 · Past); Kythera Biopharmaceuticals Inc (Chief Financial Officer · Oct 10, 2012 – Oct 1, 2015 · Past) | Chair, Compensation Committee · Since at least Sep 11, 2023 |
| Eric Groen Other companies: Rani Therapeutics Holdings, Inc. (General Counsel · Mar 22, 2022 – Mar 21, 2024 · Past) | General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development · Since at least Jul 1, 2025 |
| Caroline Jewett | Head of Quality · Jun 30, 2023 – Feb 19, 2024 · Past |
| Gabe Woodward | Director · Jan 25, 2023 – Feb 17, 2023 · Past |
| James L. Tyree | Lead Independent Director · Since at least Aug 27, 2025 |
| Jason Litten | Chief Medical Officer · Since at least Sep 9, 2026 |
| John Thomas | Director · Since at least Jan 25, 2023 |
| Joseph Cappello | Chief Technical Officer · Since at least Mar 14, 2025 |
| Lourie S Zak | Chief Financial Officer · Aug 28, 2023 – Dec 18, 2024 · Past |
| Mary Mirabelli | Director · Since at least Jun 16, 2026 |
All 16 people
| Person | Seat |
|---|---|
| Matt Pulisic | Chief Financial Officer · Since at least Jan 12, 2026 |
| Qian Zhang | Vice President, Clinical Sciences · Since at least Nov 5, 2026 |
| Ralph Smalling | Vice President, Head of Regulatory Affairs · Since at least Jun 4, 2026 |
| Sean Ryder | General Counsel · Jan 25, 2023 – May 12, 2025 · Past |
| Thomas Zindrick | President and Chief Executive Officer · Since at least May 11, 2026 |
| Tony Yu | Chief Scientific Officer · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Genelux Corporation.